All In Biotech

Drug Trial Radar · NCT05014815

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 272 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

272

Actual

Start

Nov 16, 2021

Primary completion

Sep 4, 2024

Study completion Sep 4, 2024

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Aug 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to other parts of the body.

Conditions

  • Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)
  • Nonsmall Cell Lung Cancer, Stage IIIB
  • Nonsmall Cell Lung Cancer, Stage IV

Interventions

  • OciperlimabDrug

    900 mg intravenously (IV) once every 3 weeks (Q3W)

  • TislelizumabDrug

    200 mg IV Q3W

  • CarboplatinDrug

    Area under the concentration-time curve (AUC) of 5 or 6, administered on Day 1 of each 21-day cycle

  • PaclitaxelDrug

    75 or 200 mg per square meter (mg/m²) of body surface area, administered on Day 1 of each 21-day cycle

  • Nab paclitaxelDrug

    100 mg/m², administered intravenously on Days 1, 8, and 15 of each 21-day cycle

  • CisplatinDrug

    75 mg/m², administered intravenously on Day 1 of each 21-day cycle

  • PemetrexedDrug

    500 mg/m² administered intravenously on Day 1 of each 21-day cycle

  • PlaceboDrug

    Administered intravenously Q3W to match ociperlimab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: From randomization up to the final efficacy analysis data cut-off date of 04 September 2024; Up to 33 months

Locations

64 sites in 8 countries. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trials

    Los Angeles, California

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Comprehensive Cancer Center of Nevada

    Las Vegas, Nevada

  • Rj Zuckerberg Cancer Center

    New Hyde Park, New York

  • North Shore Hematology Oncology Associates Dba New York Cancer and Blood Specialists (New York)

    New York, New York

  • North Shore Hematology Oncology Associates Dba New York Cancer and Blood Specialists

    Port Jefferson Station, New York

  • Ny Cancer and Blood Specialists

    The Bronx, New York

  • Xcancerdayton Physician Network

    Dayton, Ohio

  • Tennessee Cancer Specialist

    Knoxville, Tennessee

  • Texas Oncology Tyler Longview

    Austin, Texas

  • Cancer Care Northwest

    Spokane Valley, Washington

  • Border Medical Oncology

    East Albury, New South Wales, Australia

  • Northern Beaches Hospital

    Frenchs Forest, New South Wales, Australia

  • Port Macquarie Base Hospital

    Port Macquarie, New South Wales, Australia

  • Townsville University Hospital

    Douglas, Queensland, Australia

  • Toowoomba Hospital

    Toowoomba, Queensland, Australia

  • Launceston General Hospital

    Launceston, Tasmania, Australia

  • Peninsula and South Eastern Haematology and Oncology Group

    Frankston, Victoria, Australia

  • Olivia Newton John Cancer Wellness and Research Centre

    Heidelberg, Victoria, Australia

  • Klinik Penzing Wien, Abteilung Fur Atemwegs

    Vienna, Austria

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Xinqiao Hospital Affiliated to the Army Medical University

    Chongqing, Chongqing Municipality, China

  • Daping Hospital, Third Military Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Cancer Center of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Jingzhou Central Hospital

    Jingzhou, Hubei, China

  • The First Peoples Hospital of Chenzhou

    Chenzhou, Hunan, China

  • Changzhou Cancer Hospital

    Changzhou, Jiangsu, China

  • Ansteel Group General Hospital

    Anshan, Liaoning, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Liaocheng Peoples Hospital

    Liaocheng, Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • The First Peoples Hospital of Kashgar

    Kashgar, Xinjiang, China

  • Zhejiang Provincial Peoples Hospital

    Hangzhou, Zhejiang, China

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.